

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

<b>Product Name:</b>	SELECTRA INVESTMENTS SICAV – J. LAMARCK PHARMA CLASS B
<b>ISIN:</b>	LU1224032463
<b>Currency:</b>	EUR
<b>Management Company:</b>	TMF Fund Management S.A. (the “Management Company”)
<b>Contact Details:</b>	<a href="mailto:legal.fundmanagement@tmf-group.com">legal.fundmanagement@tmf-group.com</a>
<b>Website:</b>	<a href="https://www.tmf-group.com/en/locations/emea/luxembourg/selectra-investments-sicav/">https://www.tmf-group.com/en/locations/emea/luxembourg/selectra-investments-sicav/</a>
<b>Call number:</b>	+352 42 71 71 1
<b>Competent Authority:</b>	Commission de Surveillance du Secteur Financier (CSSF)
<b>Document valid as at:</b>	01/01/2023

**PLEASE NOTE: YOU ARE ABOUT TO PURCHASE A PRODUCT WITH COMPLEX FEATURES THAT MAY BE DIFFICULT TO UNDERSTAND**

## What is this product?

<b>Type:</b>	SELECTRA INVESTMENTS SICAV (the “Fund”) is organized as a "société d'investissement à capital variable" in the Grand Duchy of Luxembourg. It is organized as a "société anonyme" under the Luxembourg law of 10 August 1915 on commercial companies and qualifies as an Undertaking for Collective Investment in Transferable Securities under the Luxembourg law of 17 December 2010 on undertakings for collective investment (UCIs).
<b>Term:</b>	The product has no maturity date. The product is a share class of the sub-fund SELECTRA INVESTMENTS SICAV – J. LAMARCK PHARMA (the “Sub-Fund”). SELECTRA INVESTMENTS SICAV is a fund incorporated as an open-ended umbrella investment company with variable capital.
<b>Objectives:</b>	The main objective of this Sub-Fund is to profit from increasing share prices in the pharmaceutical sector worldwide. The focus is on mature top tier pharmaceutical companies and companies with interesting pipeline of products in development in a single or numerous markets. The followed investment policy will enable the Sub-Fund to increase overall return by active stock selection of companies, offering the most promising technology platform.
<b>Strategy:</b>	To achieve this investment objective, the Sub-Fund will take long positions in these shares issued mainly by worldwide issuers. In order to lower overall risk the Sub-Fund will NOT invest in derivatives (such as single stock futures, index futures, warrants or options) to meet the Sub-Fund’s investment objective. The Sub-Fund may use financial derivative instruments for the purpose of hedging currency risks only. The Sub-Fund may invest up to 10% of its total net assets in shares/units of UCITS and/or other UCIs (including ETF). Where the Sub-Fund invests in a UCITS and/or other UCIs linked to the Investment Manager of the Sub-Fund, the manager of the underlying UCITS respectively UCIs cannot charge subscription or redemption fees on account of the investment. The aggregate maximum annual management fees that will be charged by the underlying UCITS in which the Sub-Fund invests is 3% of their aggregate net asset values per annum. The effective management fees charged to the Sub-Fund by the underlying UCITS will be disclosed in the Fund’s annual report.
<b>Dividend Policy:</b>	Capitalization.
<b>Intended retail investor:</b>	The minimum initial subscription amount and minimum holding is EUR 5,000.

## What are the risks and what could I get in return?

### Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets.

We have classified this product as class 4 out of 7, which is a medium risk class.

The category shown is not guaranteed to remain unchanged and may shift over time.

**Be aware of currency risk. If you are a non-Eurozone investor, you will receive payments in a different currency than the reference currency, so the final returns you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

This product does not include any protection from future market performance so you could lose some or all of your investment.

Investors who seek to invest worldwide in shares of companies active in the pharmaceutical sector. Investor who is prepared to take the higher risks associated with investments in the stock markets in order to maximise the return.

A long-term investment horizon, at least 5 years, is required in order to ride out potentially adverse market trends.

You can lose all invested capital, or you can bear the risk of incurring additional financial commitments or obligations, including contingent liabilities in addition to the capital invested in the PRIIP, and where applicable, whether the PRIIP includes capital protection against market risk, and the details of its cover and limitations, in particular with respect to the timing of when it applies.

The tax legislation of your home EU member state may have an impact on the actual payout.

Advisors, distributors or any other person advising on, or selling, the KID will provide information detailing any cost of distribution that is not already included in the costs specified below, so as to enable you to understand the cumulative effect that these aggregate costs have on the return of the investment, where applicable.

### Performance Scenarios

Investment: EUR 1,000		1 year	3 years (recommended holding period)
Stress scenario	What you might get back after costs	EUR 377.00	EUR 388.00
	Average return each year	-62.30 %	-20.40 %
Unfavourable scenario	What you might get back after costs	EUR 823.00	EUR 743.00
	Average return each year	-17.70 %	-8.60 %
Moderate scenario	What you might get back after costs	EUR 1,052.00	EUR 1,088.00
	Average return each year	5.20 %	2.90 %
Favourable scenario	What you might get back after costs	EUR 1,354.00	EUR 1,746.00
	Average return each year	35.40 %	24.90 %

This table shows the money you could get back over the recommended holding period, under different scenarios, assuming that you invest EUR 1,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies and are not an exact indicator for future performance.

The scenarios are based on share price total return.

What you get will vary depending on how the underlying investments perform, how the overall market performs and how long you keep the investment. The stress scenario shows what you might get back in extreme market circumstances, and it does not consider the situation where SELECTRA INVESTMENTS SICAV – J. LAMARCK PHARMA is not able to pay you on its liquidation.

### What happens if TMF Fund Management S.A. is unable to pay out?

No rewarding and no guaranteed systems are in place for shareholders in case the Management Company is unable to pay out. The Fund has assets which are distinct and separate from those of the Management Company; moreover, for all the obligations entered into by the Sub-Fund, the latter shall respond with and to the extent of the assets of such sub-fund. No action or claims by creditors of the Management Company, the depositary bank or any sub-custodian (or in the latter's interest) is admitted on the assets of the Sub-Fund. Any action or claim by creditors of each shareholder is admitted only on the shareholding held by

latter. The Management Company shall not use under any circumstance, in its own interest or in the interest of third parties, any assets or good belonging and/or related to the Fund. In principle, the lack of a rewarding and guaranteed system by the Management Company should not have any impact on the Fund's assets.

## What are the costs?

### Costs over time

The Reduction in Yield ("RIY") shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest EUR 1,000. The figures are estimates and may change in the future.

The person selling you or advising you about this product may change you other costs, if so, this person will provide you with information about these costs and show you the impact that all costs will have on your investment over time.

Investment: EUR 1,000	If you cash in after 1 year	If you cash in after 3 years
Total costs	EUR 58.00	EUR 114.00
Impact on return (RIY) per year	5.80 %	3.80 %

### Composition of Costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

One-off costs upon entry or exit		If you exit after 3 years.
Entry costs	The impact of the costs you pay when entering your investment. This is the most you will pay, and you could pay less. This includes the costs of distribution of your product.	Up to 3.00 %
Exit costs	The impact of the costs of exiting your investment.	0.00 %
Ongoing costs taken each year		
Management fees and other administrative or operating costs	The impact of the costs that we take each year for managing your contract and your investments.	Up to 2.80 % with a minimum fee of EUR 30k for the Sub-Fund
Transaction costs	This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	0.00 %
Incidental costs taken under specific conditions		
Performance fee(*) and carried interests	The actual amount will vary depending on how well your investment performs.	0.00 %

(\*) At the end of each year, the investment manager shall be entitled to receive a performance fee from the Sub-Fund up to 10% of the appreciation of its net asset value per share.

This table shows the impact the different costs have on the investment return you might get back at the recommended holding period and the meaning of the different cost categories.

## How long should I hold it and can I take my money out early?

The Sub-Fund is open-ended and, therefore, shareholders can redeem their shares during the life of the Sub-Fund and in accordance with the Fund's prospectus.

## How can I complain?

Investors in the Fund shall address any complaint by registered mail to the Management Company. The Management Company has one (1) month from the date of receipt of the complaint to give a complete written answer to the complainant. In case this is not possible, the Management Company has to explain the reason of the delay and give the complainant a deadline for the resolution. In case the complainant is not satisfied with the answer from the Management Company, they have the possibility to make a formal complaint to the CSSF for an "out-of-court resolution of complaint".

### TMF FUND MANAGEMENT S.A. (Complaints Officer)

46A, Avenue John F. Kennedy, L-1855 Luxembourg

Tel. +352 42 71 71 1

[complaint.fundmanagement@tmf-group.com](mailto:complaint.fundmanagement@tmf-group.com)

## Other relevant information

For more information, please visit the website <https://www.tmf-group.com/en/locations/emea/luxembourg/selectra-investments-sicav/>. Except for specific revisions, this KID is updated at least every twelve (12) months.

Further information on SELECTRA INVESTMENTS SICAV is contained in the latest valid prospectus, the articles of association and additional documentation of the Fund available under the law. The information contained in this KID does not constitute a recommendation for the purchase or sale of the shares of the sub-fund SELECTRA INVESTMENTS SICAV – J. LAMARCK PHARMA.

The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the paying agent is Cornèr Banca SA, Via Canova 16, CH-6900 Lugano. The prospectus, the key information documents, the fund regulation, or the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.